European Archives - Page 1038 of 1203 - European Medical Journal

EMJ

Delaying School Start Times to Boost Adolescent Academic Performance

Sleep is becoming an increasingly scarce commodity, especially among adolescents. For a teenager to perform at maximum cognitive levels, sleep…

Review of the European Society of Medical Oncology Congress 2016

This year, Copenhagen played host to the annual ESMO Congress which took place over 5 days and welcomed 20,522 participants. During the closing press…

EMJ

Prize Winners at the ESMO Annual Meeting 2016

This year’s ESMO congress was hosted in the beautiful city of Copenhagen, Denmark. A city admired for being simultaneously traditional and modern, and…

Introducing EMJ Oncology 4.1

United Kingdom, November 15, 2016: Welcome to this year’s edition of EMJ Oncology, a must-read for all those with a passion for oncology.

State-of-the-Art Integration of Multiple Kinase Inhibitors in the Treatment of Gastrointestinal Cancers

This symposium provided an overview of the efficacy and safety of multikinase inhibitors in colorectal cancer, including treatment sequencing, followed…

Optimising Salvage Therapy in Aggressive B Cell Non-Hodgkin Lymphoma

Prof D’Amore opened the symposium by highlighting that management of patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma…

Cabozantinib as First-Line Therapy for Patients with Metastatic Renal Cell Carcinoma with Poor or Intermediate-Risk Characteristics

The oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) sunitinib is a standard first-line therapy for patients with…

Regorafenib in Metastatic Colorectal Cancer and Advanced Soft Tissue Sarcomas

Oncologists face multiple challenges when treating patients with cancer, especially if patients are elderly or if they experience adverse events (AEs).

Editor’s Pick: Muscle Dysfunction in Childhood Cancer: Biological Mechanisms and Implications for Long-Term Survivorship

Paediatric cancer treatment has advanced significantly over the last half century to a point where >80% of all childhood cancer cases survive >5 years…

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have become the standard therapy for chronic myeloid leukaemia (CML).